IP Library Granted Patent US 10,828,252
Granted Patent B2
US 10,828,252 · App. 16/043,725 · Granted Nov 10, 2020

Compositions and uses of alpha-adrenergic agents

Inventors: Frank Litvack (Los Angeles, CA); Houman Hemmati (Los Angeles, CA)
Assignee: LEVATION PHARMA LTD.
A61K9/0014A61K8/4946A61K9/0019A61K9/0048A61K31/4174A61P21/00A61P27/02A61Q1/10A61Q19/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,828,252
App. No.
16/043,725
Granted
Nov 10, 2020
Kind
B2
Abstract

The disclosure provides cosmetic and therapeutic compositions of alpha-adrenergic agents. Compositions of the disclosure may be used for topical, transdermal or parenteral administration to the eye or eyelid. The compositions of the disclosure may be used cosmetically to improve the appearance of the eye or therapeutically to treat ptosis.

Claims (13)

1. A method for increasing the vertical separation of the upper and lower eyelids of an eye of a subject, comprising administering to the exterior surface of the upper eyelid of the subject a controlled-release composition comprising an effective amount of an alpha-adrenergic agent and a permeation enhancer, wherein the effective amount of the alpha-adrenergic agent is from about 0.5 mg to 8 mg per dose and wherein the alpha-adrenergic agent is oxymetazoline or a salt thereof and wherein the increasing the vertical separation of the upper and lower eyelids is increasing the distance between the upper eyelid and midpupil to about 2 mm or more.

2. The method of claim 1 , wherein the subject does not have ptosis.

3. The method of claim 1 , wherein the composition comprises from about 3 to 6 mg of oxymetazoline or a salt thereof per dose.

4. The method of claim 1 , wherein the permeation enhancer increases skin permeation of oxymetazoline or a salt thereof by about 2-fold or greater relative to a composition without the permeation enhancer.

5. The method of claim 1 , wherein the permeation enhancer increases skin permeation of oxymetazoline or a salt thereof by about 3-fold or greater relative to a composition without the permeation enhancer.

6. The method of claim 1 , wherein the permeation enhancer increases skin permeation of oxymetazoline or a salt thereof by about 0.5 mm or more relative to a composition without the permeation enhancer.

7. The method of claim 1 , wherein oxymetazoline or a salt thereof permeates through the skin and septal fat pad.

8. The method of claim 1 , wherein the permeation enhancer is selected from ethanol, propylene glycol, dodecyl-N,N-dimethyl-aminoacetate, ethylacetate, azone, sodium dodecyl sulfate, d-limonene, oleic acid, 1,3-diphenyl-urea, N-methyl-2-pyrrolidone, beta-cyclodextrin, dimethylsulfoxide, and any combination thereof.

9. The method of claim 1 , wherein the composition further comprises one or more cosmetic excipients.

10. The method of claim 9 , wherein the cosmetic excipient is selected from sunscreens, fragrances, pigments, and antioxidants.

11. The method of claim 1 , wherein the composition further comprises a dermatologically acceptable carrier.

12. The method of claim 11 , wherein the dermatologically acceptable carrier is selected from a lotion, an oil, a cream, a butter, a gel, an ointment, a spray, a milk, and a powder.

13. The method of claim 11 , wherein the dermatologically acceptable carrier comprises a powder.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2018
From: LITVACK, FRANK; HEMMATI, HOUMAN
To: LEVATION PHARMA LTD.
Reel/Frame 046490/0586 →
Continuity (3)
Continuation PCTUS2017015181 · Jan 26, 2017
Provisional Application 62287391 · Jan 26, 2016
Related Publication 20180325806A1 · Nov 15, 2018
Cited By (3)
US 12,357,561 US 12,605,363 US 12,648,930